Brookline analyst Leah Rush Cann downgraded MEI Pharma to Hold from Buy without a price target after the company announced it is exploring strategic alternatives. The firm says extending its current cash runway beyond December 31 hinges on the cost saving and the strategic directions MEI pursues. The analyst cites increased uncertainty to the path forward for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.